LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

被引：18
|
作者：
Mato, Anthony R.
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Yoon
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal
Tam, Constantine S.
Lewis, David John
Gerson, James N.
Alencar, Alvaro J.
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Chen, Jessica
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134970
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
    Shah, Nirav N.
    Wang, Michael L.
    Brown, Jennifer R.
    Patel, Krish
    Woyach, Jennifer A.
    Wierda, William G.
    Ujjani, Chaitra S.
    Eyre, Toby A.
    Zinzani, Pier Luigi
    Alencar, Alvaro J.
    Gastinne, Thomas
    Ghia, Paolo
    Lamanna, Nicole
    Hoffmann, Marc
    Patel, Manish R.
    Flinn, Ian W.
    Gerson, James N.
    Ma, Shuo
    Coombs, Catherine C.
    Cheah, Chan Y.
    Lech-Maranda, Ewa
    Fakhri, Bita
    Kim, Won-Seog
    Barve, Minal A.
    Cohen, Jonathon B.
    Jurczak, Wojciech
    Munir, Talha
    Thompson, Meghan C.
    Roeker, Lindsey E.
    Bao, Katherine
    Cangemi, Nicholas A.
    Kherani, Jennifer F.
    Walgren, Richard A.
    Han, Hongmei
    Ruppert, Amy S.
    Mato, Anthony R.
    BLOOD, 2022, 140 : 4127 - 4132
  • [32] LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort
    Woyach, Jennifer A.
    Brander, Danielle M.
    Hu, Boyu
    Rogers, Kerry A.
    Omer, Zulfa
    Stephens, Deborah M.
    Sitlinger, Andrea
    Tan, Fenlai
    Chen, Yi
    Anthony, Stephen P.
    Chen, Yu
    Shang, Kewei
    Byrd, John C.
    BLOOD, 2024, 144 : 4623 - 4623
  • [33] Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I/II BRUIN Study
    Brown, Jennifer
    Desikan, Sai Prasad
    Nguyen, Bastien
    Won, Helen
    Tantawy, Shady I.
    McNeely, Samuel C.
    Marella, Narasimha
    Ebata, Kevin
    Woyach, Jennifer
    Patel, Krish
    Tam, Constantine S.
    Eyre, Toby A.
    Cheah, Chan Y.
    Shah, Nirav
    Ghia, Paolo
    Jurczak, Wojciech
    Balbas, Minna
    Nair, Binoj
    Abada, Paolo
    Wang, Chunxiao
    Wang, Denise
    Mato, Anthony
    Gandhi, Varsha
    Wierda, William
    LEUKEMIA & LYMPHOMA, 2023, 64 : S25 - S26
  • [34] Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study
    Coombs, Catherine C.
    Woyach, Jennifer A.
    Brown, Jennifer R.
    Ghia, Paolo
    Roeker, Lindsey E.
    Patel, Krish
    Eyre, Toby A.
    Tam, Constantine S.
    Seymour, John F.
    Shah, Nirav N.
    Flinn, Ian W.
    Cheah, Chan Y.
    Ma, Shuo
    Rhodes, Joanna M.
    Izutsu, Koji
    Jurczak, Wojciech
    Wierda, William G.
    Loubert, Angely
    Payakachat, Nalin
    Hess, Lisa M.
    Abada, Paolo
    Lamanna, Nicole
    BLOOD, 2023, 142
  • [35] Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment
    Wang, Michael L.
    Shah, Nirav N.
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Eyre, Toby A.
    Cheah, Chan Y.
    Ujjani, Chaitra S.
    Izutsu, Koji
    Ma, Shuo
    Flinn, Ian
    Alencar, Alvaro J.
    Lewis, David
    Patel, Krish
    Maddocks, Kami
    Wang, Yucai
    Munir, Talha
    Zelenetz, Andrew D.
    Balbas, Minna
    Tsai, Donald E.
    Wang, Chunxiao
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S459 - S459
  • [36] Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 16 - 16
  • [37] Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL
    Blachly, James S.
    Stephens, Deborah M.
    Ye, J. Christine
    Lamanna, Nicole
    Jain, Nitin
    Niesman, Michael
    Zhang, Kai
    Woyach, Jennifer A.
    BLOOD, 2022, 140 : 2324 - 2325
  • [38] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
    Wang, Michael L.
    Shah, Nirav N.
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Eyre, Toby A.
    Cheah, Chan Y.
    Ujjani, Chaitra S.
    Koh, Youngil
    Izutsu, Koji
    Gerson, James N.
    Flinn, Ian W.
    Tessoulin, Benoit
    Alencar, Alvaro J.
    Ma, Shuo
    Lech-Maranda, Ewa
    Rhodes, Joanna M.
    Patel, Krish
    Woyach, Jennifer A.
    Lamanna, Nicole
    Wang, Yucai
    Tam, Constantine S.
    Seymour, John F.
    Munir, Talha
    Nagai, Hirokazu
    Hernandez-Ilizaliturri, Francisco
    Kumar, Anita
    Zelenetz, Andrew D.
    Jain, Preetesh
    Nair, Binoj
    Tsai, Donald E.
    Balbas, Minna
    Walgren, Richard A.
    Abada, Paolo B.
    Wang, Chunxiao
    Zhao, Junjie
    Mato, Anthony R.
    BLOOD, 2022, 140 : 9368 - 9372
  • [39] A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study
    Song, Yuqin
    Cai, Qingqing
    Jiang, Ming
    Zhang, Lei
    Sun, Xiuhua
    Jin, Zhengming
    Li, Lanfang
    Jing, Hongmei
    Peng, Zhigang
    Yang, Haiyan
    Qi, Junyuan
    Zhou, Hui
    Yang, Wei
    Zhou, Min
    Ji, Chunyan
    Xu, Wei
    Ding, Kaiyang
    Yu, Li
    Wang, Zheng
    Liu, Nawei
    Lou, Yejiang
    Shen, Yue
    Chen, Yi
    Tan, Fenlai
    Zhu, Jun
    BLOOD, 2023, 142
  • [40] Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.
    Shah, Nirav Niranjan
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Eyre, Toby A.
    Cheah, Chan
    Ujjani, Chaitra Shankar
    Izutsu, Koji
    Ma, Shuo
    Flinn, Ian W.
    Alencar, Alvaro Jose
    Lewis, David John
    Patel, Krish
    Maddocks, Kami J.
    Wang, Yucai
    Munir, Talha
    Zelenetz, Andrew David
    Balbas, Minna
    Tsai, Donald E.
    Wang, Chunxiao
    Wang, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345